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CC BY-NC-ND license (http://creativAbstract This study was conducted to determine the efficacy of switching therapy with a
second-line luteinizing hormoneereleasing hormone (LHRH) analogue after prostate-specific
antigen (PSA) progression for advanced prostate cancer. We enrolled 200 patients, from
December 2005 to September 2013, with nodal positive, metastatic prostate cancer or disease
progression after definite treatment receiving continuous LHRH analogue therapy with monthly
depot leuprorelin(sc) acetate 3.75 mg/vial (LA) or goserelin acetate(sc) 3.6 mg/vial (GA). If
the patients had castration-resistant prostate cancer, the treatment choice of switching ther-
apy (from LA to GA or from GA to LA) prior to starting chemotherapy was given. The LH, testos-
terone level, and PSA change were recorded. The records showed that there were 127 patients
receiving LA as initial ADT therapy, whereas the other 73 patients were in GA therapy. A total
of 92 patients received LHRH analogue switching therapy (54 patients switched from LA to GA
and 38 switched from GA to LA). The effect of LH and testosterone reduction prior to and after
switching therapy was comparable between the two groups, and increased PSA level after
3 months of treatment was seen in both groups (median PSA: 15.7e67.7 ng/mL in the LA to
GA group; 15.2e71.4 ng/mL in the GA to LA group). This study concluded that switching ther-
apy for patients with PSA progression after ADT has no efficacy of further PSA response.
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Table 1 Baseline patient characteristics.
Leuprorelin
No. (％)
Goserelin
No. (％)
p
N 127 73
Age (y) 77.1  8.5 76.7  8.4 0.757
Initial PSA (ng/mL) 404.1  1293.2 583.3  1689.2 0.413
Gleason score 2e4 2 (1.8) 1 (1.6) 0.249
5e7 54 (49.5) 24 (38.1)
8e10 53 (48.6) 38 (60.3)
Initial T stage 1 9 (9.1) 4 (7.4) 0.198
2 22 (22.2) 5 (9.3)
3 52 (52.5) 36 (66.7)
4 16 (16.2) 9 (16.7)
Initial stage 1 5 (5.2) 1 (1.9) 0.113
2 16 (16.7) 3 (5.8)
3 34 (35.4) 17 (32.7)
4 41 (42.7) 31 (59.6)
PSA Z prostate-specific antigen.
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Androgen deprivation therapy (ADT) with luteinizing hor-
moneereleasing hormone (LHRH) analogue has been the
standard treatment for advanced prostate cancer since the
demonstration of the hormone dependence of prostate
cancer cells. In the past 20 years,medical castrationwith the
use of LHRH analogue has been proved as a tolerated and
effective option for advanced prostate cancer because of its
survival benefits [1e4]. It has also become the replacement
for surgical castration (bilateral orchiectomy) because of its
convenience and avoidance of body integrity loss.
ADT with LHRH analogues decreases PSA and improves
clinical symptoms in about 90% of patients. However, lim-
itation in the duration of response for the drug exists and
after that castration-resistant prostate cancer (CRPC) de-
velops. Different LHRH analogues are considered equiva-
lent [4e6], so there was no rule about changing one LHRH
analogue to another in the former concept prior to starting
therapy for CRPC. However, various agents have different
chemical structures, so it is possible that they could result
in different patient responses. A study from multiple in-
stitutions in Canada demonstrated the efficacy of second-
line LHRH analogues after disease progression [7]. They
showed PSA decrease after switching therapies, and the
decrease was more significant in the group switching from
leuprolide acetate (LA) to goserelin acetate (GA). Accord-
ing to the hypothesis of divergent way of action from
various LHRH analogues and the possible efficacy of
switching therapy, we performed this study to determine if
changing LHRH analogues would lead to PSA response.
Methods
Patient selection, treatment, and follow-up
We performed a prospective study from December 2005 to
September 2013 in a single medical institute. We identified
patients with initially diagnosed nodal positive (N1), met-
astatic (M1) prostate cancer and disease progression after
definite treatment including radical prostatectomy and
radiotherapy. The patients received continuous LHRH
analogue therapy as the initial ADT with Depot leupror-
elin(sc) acetate 3.75 mg/vial (LA) or goserelin acetate(sc)
3.6 mg/vial (GA) every month, and the concomitant
nonsteroidal antiandrogen was only allowed for 1e4 weeks
when we initiated ADT to avoid flare-up phenomenon.
Other patients receiving hormonal manipulation such as
diethylstilestrol, steroidal antiandrogen, or ketaconazole
were excluded. Furthermore, if patients had met the
criteria of CRPC, defined as two consecutive PSA increases
while on ADT and reaching castration testosterone level (<
0.2 ng/mL), we gave these patients the choice of switching
therapy from the original LHRH analogues to another
regimen (LA to GA or GA to LA) prior to starting chemo-
therapy treatment. The second-line LHRH analogue was
used for at least 3 months to determine the PSA response.
Baseline data including patient demographics, initial TNM
stage, baseline PSA, and Gleason score were collected. The
LH, testosterone, and PSA level were checked every
3 months and whether patients could reach the cutoff value(LH < 1.0 mIU/mL and testosterone level < 0.2 ng/mL or
<0.1 ng/mL) was determined at the first 3-month follow-
up. The PSA level prior to switching therapy and every
3 months after the therapy were recorded to analyze the
treatment response. This study was approved by the CGMH
Institutional Review Board.
Statistical analysis
The baseline demographic data of patients and the efficacy
of lowering hormone level were analyzed with Fisher’s
exact test, Pearson’s Chi-square test, and two-tailed in-
dependent t test. McNemar test, Wilcoxon signed rank test,
and ManneWhitney U test were used to show the signifi-
cance of LH or testosterone change and PSA response. All
analyses were carried out using SPSS software, version 17.0
(SPSS Inc., Chicago, IL, USA).
Results
From December 2005 to September 2013, a total of 200
patients met the inclusion criteria. The baseline data of
patients are shown in Table 1. Overall, 127 patients
received LA as the initial ADT therapy and the other 73
patients were in GA therapy. There was no statistical dif-
ference in terms of age, initial TNM stage, Gleason score, or
baseline PSA between the groups of patients receiving LA or
GA. The efficacy of reducing LH less than 1.0 mIU/mL
(73.2% in LA and 74% in GA group; p Z 0.909) and testos-
terone less than 0.2 ng/mL (81.9% in LA and 80.8% in GA
group; pZ 0.851) was equivalent. As regards the extremely
low testosterone level of less than 0.1 ng/mL (the lowest
sensitive level in our clinical laboratory according to the
new rapid polyelectrolyte-based immunofiltration tech-
nique [8]), there were 49.6% patients in the LA group and
47.9% patients in the GA group who could reach this level.
Switching therapy
In the study population, there were 92 patients included in
the switching therapy with the available clinical data. Fifty-
Switching LHRH analogue for CRPC 569four patients switched from LA to GA and 38 patients
switched from GA to LA because of PSA progression. In the
univariate analysis, there was no statistically significant
difference in patient age, initial Gleason score, and dura-
tion of first LHRH analogue usage. There was also no sta-
tistically significant difference in median PSA prior to the
first or secondary LHRH analogue between the two groups
(Table 2). After rechallenging with the second-line LHRH
analogues, the effect of LH and testosterone reduction was
the same between the two groups (Table 3). About PSA, the
increase in level after 3 months of treatment was seen in
both groups (median PSA: 15.7e67.7 ng/mL in the LA to GA
group and 15.2e71.4 ng/mL in the GA to LA group; Table 4)
and the result of absolute PSA change showed no significant
difference (pZ 0.341). There were 36 patients (17 patients
in the LA to GA group and 19 patients in the GA to LA group)
who kept second-line LHRH analogue without definite CRPC
treatment and receiving the 6-month PSA follow-up. The
PSA level continued to rise (204.2 ng/mL and 174.4 ng/mL)
at the 6-month follow-up.Table 2 Univariate analysis of switching therapy.
Overall
Patient No. (%) 92
Mean age at PC diagnosis (y) 77.9  7.5
Gleason score (%)
 6 18
 7 74
Mean duration of first analogue (mo) 30.0  19.5
Median PSA (ng/mL)
At first LHRH analogue start (range) 14.4 (3.42e947.8)
At second LHRH analogue start (range) 15.8 (3.05e698.46
GA Z goserelin acetate; LA Z leuprorelin acetate; LHRH Z lut
PSA Z prostate-specific antigen.
Table 3 Hormonal suppression effect of switching therapy.
Primary medicine
Goser
LH <1.0
Leuprorelin <1.0 mIU/mL 28
Leuprorelin 1.0 mIU/mL 7
Leupr
LH <1.0
Goserelin <1.0 mIU/mL 26
Goserelin 1.0 mIU/mL 2
Primary medicine
Gose
Testosterone <2.0
Leuprorelin <0.2 ng/mL 48
Leuprorelin 0.2 ng/mL 0
Leup
Testosterone <2.0
Goserelin <0.2 ng/mL 29
Goserelin 0.2 ng/mL 0
LH Z luteinizing hormone.
a McNemar test.Discussion
Based on the dependence of prostate cancer cells on
testosterone, surgical or chemical castration is used for
stopping the growth of cancer cells. When choosing the
method of castration, the goal is to achieve a low testos-
terone level. Historically, testosterone level below0.5 ng/mL
was used as the standard level of castration [9]. However,
after the development of new assays and more sensitive
tests, the level to achieve castration seems to be more
strictly defined [8,10]. Recent studies have measured the
testosterone level after bilateral orchiectomy based on
chemiluminescence and reported themean value to be about
0.2 ng/mL [3,11e13]. Therefore, < 0.2 ng/mL was assumed
to be an adequate castration level when using chemical
castration [14]. Oefelein and Resnick [15] advocated for the
concept of “the lower, the better” while defining the level of
castrationdwhich is why we analyzed the efficacy of
lowering testosterone not only by 0.2 ng/mL but also by
0.1 ng/mL (the lowest sensitive level in our institute).LA to GA GA to LA p
54 38
77.6  7.6 78.4  7.5 0.591
8 10 0.171
46 28
33.9  22.2 24.3  13.1 0.11
28.2 (3.42e947.8) 8.76 (4.1e698.5) 0.087
) 15.7 (3.05e213.29) 15.2 (4.05e698.46) 0.701
einizing hormoneereleasing hormone; PC Z prostate cancer;
Secondary medicine pa
elin Goserelin
mIU/mL 1.0 mIU/mL
11 0.481
8
orelin Leuprorelin
mIU/mL 1.0 mIU/mL
8 0.109
2
Secondary medicine pa
relin Goserelin
ng/mL 2.0 ng/mL
1 >0.99
5
rorelin Leuprorelin
ng/mL 2.0 ng/mL
0 >0.99
9
Table 4 PSA response of switching therapy.
N Median PSA (IQR, ng/mL) Absolute PSA change
(3 mo & 0 mo)
pa
At second LHRH analogue
start (0 mo)
3 mo after second
LHRH analogue
N 6 mo after second
LHRH analogue
Leuprorelin to
goserelin
54 15.7 (5.4, 69.1) 67.7 (10.8, 156.4) 17 204.2 (21.5, 320.4) 34.2 0.085
Goserelin to
leuprorelin
38 15.2 (4.8, 149.2) 71.4 (8.0, 134.5) 19 174.4 (24.3, 207.3) 28.2 0.918
p Z 0.341b
IQR Z interquartile range; LHRH Z luteinizing hormoneereleasing hormone; PSA Z prostate-specific antigen.
a Wilcoxon signed rank test.
b ManneWhitney U test.
570 Y.-C. Shen et al.In this study, about 80% of patients with nodal positive,
metastatic disease or disease progression after definite
therapy receiving LA or GA could achieve a satisfactory level
of testosterone. About 70% patients could have an LH level
of less than 1 mIU/mL. Because the pattern of change in LH
was similar to that in testosterone, studies seldom showed
the level of LH [16,17]. Whichever regimen is used for ADT,
the efficacy of hormonal control was similar and the per-
centage of patients who could attain the lowest testos-
terone level (< 0.1 ng/mL) was around 50% in both groups.
We found that a proportion of PC patients (w20%) did not
reach the goal of castration with testosterone of less than
0.2 ng/mL, and the other series also revealed similar re-
sults, in which about 10e37% failed to achieve low testos-
terone level [18e21]. In general, castration level can be
achieved 4 weeks after the treatment [13], and the duration
of testosterone suppression ranges from 9.3 months to
45 months [1,3,13,16]. Different series showed variable
duration because of variable baseline conditions. Nadir PSA,
time to nadir PSA, baseline PSA, tumor grade, and pre-
treatment testosterone are predictive of patient response.
For these patients with PSA progression, switching to
another LHRH analogue or adding other secondary hor-
monal agent was offered as a treatment option. In our
setting, some CRPC patients hesitated to proceed to
chemotherapy because of their fear of side effects and the
inconvenience of hospitalization, so we offered them
another alternative treatment with second-line LHRH ana-
logues prior to chemotherapy. Lawrentschuk et al [7] re-
ported a second-line LHRH analogue having the efficacy of
PSA decrease in 70% patients, and the duration of response
after switching was about 5 months. They also found that
the trend was more significant in the group that switched
from LA to GA. They advocated the role of second-line
LHRH analogues. However, only retrospective evaluation
was performed, and no testosterone or LH data were made
available. Furthermore, no other series has so far dupli-
cated their result.
Increased PSA after ADT generally indicates disease
deterioration. Some experts doubt if the failure of the
initial LHRH analogue is attributable to the mutant
castration-resistant cell development. They assume that
PSA progression ensues only because of the tolerance to
one LHRH analogue, so another similar drug with different
chemical structures may result in PSA decrease again. Many
questions exist regarding the optimal dosing, duration, androute of administration of LHRH analogues [22e26]. The
dose of leuprorelin used in this study is only 3.75 mg, in
comparison with 7.5 mg used in the United States. We still
cannot find any difference in androgen suppression be-
tween leuprorelin and goserelin. Other series also showed
similar results [27e29].
In our study, we did not find any indication that second-
line LHRH analogues resulted in further decrease in PSA
even under equivalent low LH and testosterone levels prior
to and after switching therapy. Although different mecha-
nisms of action of different drugs may exist, there was no
proven effect on PSA response and survival by rechallenging
with alternative LHRH analogues. The limitation of our
study was the small case number and outcome such as
progression-free survival or overall survival was not shown
because of the variable of subsequent therapy. A potential
benefitdwhether in survival or symptom reliefdof second-
line LHRH analogues may exist in different subsets of pa-
tients. Further prospective randomized study is necessary
to determine its efficacy.
In conclusion, this study revealed the equivalent effect
of LA and GA in initial testosterone control for advanced
prostate cancer. In subsequent switching therapy for
patients with PSA progression after ADT, there was no
further PSA response after switching to secondary LHRH
analogue.
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